Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

André N Vis

Showing results (1-10 of 152) with videos related to

Pageof 16
Sort By:
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 20, 2002
Does PSA screening reduce prostate cancer mortality?André N Vis
The Lancet. Oncology|July 3, 2025
RADIOSA and the management of oligorecurrent prostate cancer: a step forward, but the journey continuesAndré N Vis
European Urology Oncology|May 7, 2025
Reply to Giacomo Gallo, Alessio Guidotti, Riccardo Lombardo, and Cosimo De Nunzio's Letter to the Editor re: Rosemarijn H. Ettema, Jan-Jaap J. Mellema, Dennie Meijer, et al. Early Oncological Outcomes in Patients Who Underwent Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging Before Radical Prostatectomy and Extended Pelvic Lymph Node Dissection. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2024.11.003André N Vis, Rosemarijn H Ettema
BJU International|June 30, 2009
Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathwaysAndré N Vis, Fritz H Schröder
BJU International|July 24, 2009
Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductaseAndré N Vis, Fritz H Schröder
European Urology|December 4, 2018
Reply to Herney Andrés García-Perdomo's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75:410-8. High-volume Disease Has a Different Standard of Care: Is Local Treatment Really Beneficial in Low-volume Metastatic Prostate Cancer?Liselotte M S Boevé, André N Vis
European Urology|January 9, 2019
Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8André N Vis, Liselotte M S Boevé
European Urology Focus|June 21, 2025
Re: Matthew J. Roberts, Giorgio Gandaglia, Daniela E. Oprea-Lager, et al. Pelvic Lymph Node Dissection in Prostate Cancer: Evidence and Implications. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.03.004André N Vis, Bernard H E Jansen-Stensland
Nederlands Tijdschrift Voor Geneeskunde|February 20, 2020
[Androgen receptor inhibitors in prostate cancer: new drugs, but for which patient?]André N Vis, R J A van Moorselaar
The Journal of Urology|December 23, 2020
Editorial CommentRoderick C N van den Bergh, André N Vis
Pageof 16

Showing results (1-10 of 152) with videos related to

Sort By:
Pageof 16
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 20, 2002
Does PSA screening reduce prostate cancer mortality?André N Vis
The Lancet. Oncology|July 3, 2025
RADIOSA and the management of oligorecurrent prostate cancer: a step forward, but the journey continuesAndré N Vis
European Urology Oncology|May 7, 2025
Reply to Giacomo Gallo, Alessio Guidotti, Riccardo Lombardo, and Cosimo De Nunzio's Letter to the Editor re: Rosemarijn H. Ettema, Jan-Jaap J. Mellema, Dennie Meijer, et al. Early Oncological Outcomes in Patients Who Underwent Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging Before Radical Prostatectomy and Extended Pelvic Lymph Node Dissection. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2024.11.003André N Vis, Rosemarijn H Ettema
BJU International|June 30, 2009
Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathwaysAndré N Vis, Fritz H Schröder
BJU International|July 24, 2009
Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductaseAndré N Vis, Fritz H Schröder
European Urology|December 4, 2018
Reply to Herney Andrés García-Perdomo's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75:410-8. High-volume Disease Has a Different Standard of Care: Is Local Treatment Really Beneficial in Low-volume Metastatic Prostate Cancer?Liselotte M S Boevé, André N Vis
European Urology|January 9, 2019
Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8André N Vis, Liselotte M S Boevé
European Urology Focus|June 21, 2025
Re: Matthew J. Roberts, Giorgio Gandaglia, Daniela E. Oprea-Lager, et al. Pelvic Lymph Node Dissection in Prostate Cancer: Evidence and Implications. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.03.004André N Vis, Bernard H E Jansen-Stensland
Nederlands Tijdschrift Voor Geneeskunde|February 20, 2020
[Androgen receptor inhibitors in prostate cancer: new drugs, but for which patient?]André N Vis, R J A van Moorselaar
The Journal of Urology|December 23, 2020
Editorial CommentRoderick C N van den Bergh, André N Vis
Pageof 16